Street Calls of the Week
Investing.com - JMP Securities has reiterated its Market Outperform rating and $87.00 price target on Structure Therapeutics (NASDAQ:GPCR), currently trading at $21.79. According to InvestingPro data, analyst targets range from $37 to $120, suggesting significant upside potential. The company’s stock has shown resilience with strong financial health metrics following the publication of Phase 3 ATTAIN data for Eli Lilly’s orforglipron in the New England Journal of Medicine.
The NEJM publication revealed that while orforglipron showed some potentially concerning liver safety events, all had alternative causes, with the authors concluding the drug has no liver safety signal after thorough evaluation. This clean liver safety profile across thousands of individuals over extended dosing periods is viewed as positive for Structure Therapeutics’ aleniglipron, given the similar structures of the compounds. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 20.48 and more cash than debt on its balance sheet.
The market had previously expressed disappointment with orforglipron’s weight loss results, which showed 9% placebo-adjusted weight loss using the conservative treatment-regimen estimand (12% using the efficacy estimand). The study authors, however, supported the approximately 10% weight loss achieved, noting it is linked to meaningful cardiometabolic benefits.
Several theories were proposed for why orforglipron did not demonstrate greater weight loss, including differences in trial design and population, a higher percentage of male participants who typically lose less weight on incretin therapies, variable responses to incretins, and dietary recommendations during the trial.
Structure Therapeutics remains on track to report 36-week Phase 2b data for aleniglipron before the end of 2025, with JMP expressing optimism that the drug could outperform orforglipron. The company’s next earnings report is scheduled for November 12, 2025. Discover more detailed analysis and 8 additional key insights about Structure Therapeutics with a subscription to InvestingPro, including exclusive Fair Value assessments and comprehensive financial health scores.
In other recent news, Structure Therapeutics has been the focus of several analyst updates. Cantor Fitzgerald reiterated its Overweight rating with a $65.00 price target, emphasizing the significance of upcoming Phase 2B obesity trial results for its oral GLP-1 drug candidate, aleniglipron, expected by the end of 2025. Guggenheim also maintained a Buy rating but slightly lowered its price target to $90.00, aligning with Structure Therapeutics’ reaffirmation of its second-quarter 2025 earnings update. JMP Securities followed suit by adjusting its price target to $87.00 while maintaining a Market Outperform rating, anticipating a potential increase in share value based on upcoming data from Eli Lilly.
Clear Street initiated coverage with a Buy rating and a $61.00 price target, highlighting the company’s potential in the oral drug market, particularly in the diabesity segment. Cantor Fitzgerald also noted the relevance of Eli Lilly’s recent Phase 3 trial data for orforglipron, suggesting potential implications for Structure Therapeutics’ aleniglipron due to structural similarities. These developments reflect a consistent interest from various firms in Structure Therapeutics’ future prospects, particularly in the context of its ongoing clinical trials and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.